What are the dosing guidelines, contraindications, adverse effects, drug interactions, and alternative therapies for rosuvastatin in adults with primary or secondary hyperlipidaemia, including dose adjustments for severe renal impairment (creatinine clearance <30 mL/min) and considerations for hepatic disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rosuvastatin: Comprehensive Clinical Guide

Dosing Guidelines

Standard Adult Dosing by Indication

For secondary prevention in adults ≤75 years with established atherosclerotic cardiovascular disease (ASCVD), initiate rosuvastatin 20-40 mg once daily as high-intensity therapy to achieve ≥50% LDL-C reduction. 1, 2 This includes patients with prior myocardial infarction, stroke, coronary revascularization, or peripheral arterial disease. 2

  • Adults >75 years with established ASCVD: Use moderate-intensity therapy (rosuvastatin 5-10 mg daily) as high-intensity therapy shows no clear additional benefit in this age group and carries higher adverse event risk. 1, 2

  • Primary prevention in adults 40-75 years without diabetes: Start rosuvastatin 5-10 mg daily (moderate-intensity) if 10-year ASCVD risk is ≥7.5%. 1, 2 Consider high-intensity therapy (20-40 mg) if 10-year risk is ≥20% or multiple risk-enhancing factors are present. 2

  • Adults with diabetes (40-75 years): Initiate moderate-intensity therapy (5-10 mg daily) for standard risk; escalate to high-intensity (20-40 mg daily) for those with additional ASCVD risk factors. 2

  • Severe hyperlipidemia (LDL-C ≥190 mg/dL): Initiate high-intensity rosuvastatin 20-40 mg daily after excluding secondary causes, regardless of other risk factors. 1, 2

Pediatric Dosing

  • Heterozygous familial hypercholesterolemia (HeFH), ages 8-<10 years: 5-10 mg once daily. 3
  • HeFH, ages ≥10 years: 5-20 mg once daily. 3
  • Homozygous familial hypercholesterolemia (HoFH), ages ≥7 years: 20 mg once daily. 3

Administration

Rosuvastatin must be taken once daily at any time of day, with or without food. 3 Three-times-weekly dosing is not recommended by ACC/AHA guidelines and provides subtherapeutic exposure with inadequate cardiovascular protection. 2

Dose Adjustments for Renal Impairment

For severe renal impairment (creatinine clearance <30 mL/min/1.73 m²) not on hemodialysis, start rosuvastatin at 5 mg once daily and do not exceed 10 mg daily. 1, 3 This is a critical safety measure due to reduced renal excretion and increased drug exposure. 2

  • Mild to moderate renal impairment: No dose adjustment required. 1, 3

  • Dialysis patients: Do not initiate statins for primary prevention in dialysis-dependent patients without pre-existing ASCVD, as trials show no cardiovascular benefit and potential increased stroke risk. 1 However, continue rosuvastatin if already receiving it at dialysis initiation. 1

Hepatic Disease Considerations

Rosuvastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis. 3

  • Obtain baseline hepatic transaminases (ALT, AST) before initiating therapy. 2
  • Monitor ALT and AST at 4-8 weeks after initiation and after any dose adjustment. 2
  • Withhold therapy if transaminases rise to ≥3× upper limit of normal and recheck in 2 weeks. 2
  • High-intensity rosuvastatin increases the risk of elevated transaminases (>2-3× ULN) in <1.5% of patients over 5 years, though no cases of hepatic failure have been reported in trials. 1

Contraindications

  • Acute liver failure or decompensated cirrhosis 3
  • Hypersensitivity to rosuvastatin or any excipients (reactions include rash, pruritus, urticaria, angioedema) 3
  • Pregnancy and lactation (not explicitly stated in provided evidence but standard for all statins)

Adverse Effects

Muscle-Related Toxicity

Myopathy and rhabdomyolysis are the most serious adverse effects. 3 Rhabdomyolysis occurs rarely (<0.06% over 4.8-5.1 years in clinical trials). 1

Risk factors for myopathy include:

  • Age ≥65 years 3
  • Uncontrolled hypothyroidism 3
  • Renal impairment 3
  • Concomitant use with certain drugs (gemfibrozil, cyclosporine, HIV protease inhibitors) 3
  • Higher rosuvastatin dosage (40 mg carries greater risk than lower doses) 3
  • Asian ethnicity 3

Clinical monitoring:

  • If muscle symptoms (cramps, weakness, myalgia) develop, stop rosuvastatin immediately and obtain creatine kinase (CK) level. 2
  • CK ≥10× upper limit of normal warrants discontinuation and further evaluation. 2
  • Myopathy incidence is <0.1% at recommended doses of 5-40 mg daily. 2

Other Adverse Effects

  • New-onset diabetes: Slight increased risk, particularly in patients with metabolic syndrome features. 2
  • Hemorrhagic stroke: Overall risk not increased with rosuvastatin versus placebo/control (hemorrhagic stroke comprised 11% of total strokes in statin groups vs. 8% in control groups). 1
  • Cognitive effects: No evidence of adverse effects on cognitive function or dementia risk. 1
  • Discontinuation rates: Statin-treated patients in trials are not more likely to discontinue than placebo-treated patients. 1

Drug Interactions and Dosage Modifications

Avoid Concomitant Use

Gemfibrozil: Avoid combination with any statin due to markedly increased risk of muscle toxicity. 1, 3 Gemfibrozil increases rosuvastatin plasma concentrations by 1.56-1.88-fold through inhibition of OATP1B1/3 and OAT3 transporters. 1 If concomitant use is unavoidable, initiate rosuvastatin at 5 mg once daily and do not exceed 10 mg daily. 3

Maximum Dose Restrictions

Concomitant Drug Maximum Rosuvastatin Dose Mechanism
Cyclosporine 5 mg once daily [3] 7-fold increase in rosuvastatin exposure; severe rhabdomyolysis risk [2]
Teriflunomide 10 mg once daily [3] OATP1B1/3 inhibition
Enasidenib 10 mg once daily [3] Transporter inhibition
Capmatinib 10 mg once daily [3] Transporter inhibition
Atazanavir/ritonavir, lopinavir/ritonavir 10 mg once daily [3] Transporter inhibition
Simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir 10 mg once daily [3] Transporter inhibition
Darolutamide 5 mg once daily [3] Transporter inhibition
Regorafenib 10 mg once daily [3] Transporter inhibition
Fostamatinib 20 mg once daily [3] Transporter inhibition
Febuxostat 20 mg once daily [3] Transporter inhibition
Tafamidis Avoid; if used, 5 mg starting dose, max 20 mg daily [3] Transporter inhibition

Not Recommended

Sofosbuvir/velpatasvir/voxilaprevir and ledipasvir/sofosbuvir: Concomitant use not recommended. 3

Fenofibrate

Fenofibrate may be considered with low- or moderate-intensity rosuvastatin (5-10 mg) only if benefits from ASCVD risk reduction or triglyceride lowering (when triglycerides ≥500 mg/dL) outweigh potential risks. 1 Fenofibrate has a 15-fold lower rhabdomyolysis rate than gemfibrozil when combined with statins (0.58 vs. 8.6 per 1 million prescriptions). 1

Antacids

Administer rosuvastatin at least 2 hours before aluminum and magnesium hydroxide combination antacids. 3

Special Population Considerations

Asian Patients

Initiate rosuvastatin at 5 mg once daily in Asian patients due to significantly higher plasma concentrations (approximately 2-fold increase). 2, 3 Consider risks and benefits when treating Asian patients not adequately controlled at doses up to 20 mg once daily. 3

Resmetirom Co-Administration (MASH/NASH)

When rosuvastatin is used with resmetirom for metabolic dysfunction-associated steatohepatitis, limit rosuvastatin to 20 mg daily. 2

Alternative and Combination Therapies

When to Add Ezetimibe

For patients with severely elevated cholesterol on maximum rosuvastatin therapy (40 mg), add ezetimibe 10 mg daily to achieve an additional 15-25% LDL-C reduction. 4 This is preferred over sequential monotherapy trials when baseline LDL-C remains very high. 4

Target LDL-C goals:

  • Clinical ASCVD: <55 mg/dL with ≥50% reduction from baseline 4
  • No ASCVD but major risk factors: <70 mg/dL 4
  • Primary prevention with elevated risk: <100 mg/dL 4

Alternative Statins

If rosuvastatin is not tolerated or contraindicated:

  • Atorvastatin 40-80 mg daily: High-intensity alternative (≥50% LDL-C reduction) 1, 5
  • Atorvastatin 10-20 mg daily: Moderate-intensity alternative (30-49% LDL-C reduction) 5
  • Pravastatin 40 mg daily: Moderate-intensity option with minimal CYP450 metabolism 1
  • Simvastatin 20-40 mg daily: Moderate-intensity option (avoid 80 mg due to myopathy risk) 1

Comparative efficacy: Rosuvastatin 10 mg produces significantly greater LDL-C reduction than atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 40 mg. 2, 6

Monitoring Protocol

Baseline Evaluation

Before initiating rosuvastatin:

  • Obtain fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) 1, 2
  • Measure baseline creatine kinase (CK), ALT, and AST 2
  • Screen for active liver disease, pregnancy, or unexplained transaminase elevations 2
  • Review concomitant medications for drug interactions 2
  • Counsel women of childbearing potential about contraception 2

Follow-Up Monitoring

  • 4-8 weeks after initiation: Repeat fasting lipids, ALT, and AST. 2 If LDL-C goals are not met and labs are acceptable, increase dose by one increment (5→10→20→40 mg). 2
  • After dose adjustment: Repeat lipid panel at 3-4 months. 2
  • First year: Monitor lipids and liver enzymes every 3-4 months. 2
  • Thereafter: Monitor every 6 months. 2
  • Each visit: Assess for muscle symptoms (pain, tenderness, weakness). 4

Common Pitfalls to Avoid

  1. Do not use moderate-intensity doses (5-10 mg) for secondary prevention in patients ≤75 years—high-intensity therapy (20-40 mg) is required to maximize cardiovascular event reduction. 2

  2. Do not automatically start all patients at 10 mg without considering ethnicity and renal function—Asian patients and those with severe renal impairment require the lower 5 mg starting dose to avoid excessive drug exposure and myopathy risk. 2, 3

  3. Do not prescribe rosuvastatin three times weekly—this approach lacks guideline support, delivers subtherapeutic exposure, and compromises proven cardiovascular benefit. 2

  4. Do not combine rosuvastatin with gemfibrozil—this combination markedly increases rhabdomyolysis risk and should be avoided. 1, 3

  5. Do not exceed 5 mg daily when co-administering with cyclosporine or other immunosuppressants—these drugs cause 7-fold increases in rosuvastatin exposure with severe muscle toxicity risk. 2, 3

  6. Do not initiate statins for primary prevention in dialysis patients—trials show no benefit and potential harm. 1

  7. Do not continue rosuvastatin if CK rises to ≥10× upper limit of normal or if unexplained muscle symptoms develop—stop immediately and evaluate for rhabdomyolysis. 2

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

High-Intensity Statin Therapy with Rosuvastatin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Management of Persistent Hyperlipidemia on Maximum-Dose Rosuvastatin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5
Guideline

Atorvastatin Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the preferred initial dose of rosuvastatin (a statin) for a patient with dyslipidemia, 20mg or 40mg, considering factors such as cardiovascular disease risk and potential side effects?
What is the recommended dosing for Rosuvastatin (rosuvastatin) in patients with hyperlipidemia?
What is the optimal starting dose of rosuvastatin for a patient with a total cholesterol of 214 mg/dL, elevated LDL cholesterol, and elevated triglycerides?
What is the recommended dosing for rosuvastatin (a high intensity statin) in an adult patient with high risk of cardiovascular events, possibly with established atherosclerotic cardiovascular disease or risk factors like diabetes, hypertension, or elevated Low Density Lipoprotein (LDL) cholesterol levels?
What is the starting dose of rosuvastatin (Crestor) for patients with hyperlipidemia?
What laboratory tests and interpretation criteria are used to diagnose menopause in a woman aged 45 or older with at least 12 months of amenorrhea?
Is a daily dose of 2.5 mg of escitalopram effective for an adult patient?
In a 7‑year‑old child with chronic diarrhea and colonoscopy showing skip lesions with terminal ileum inflammation consistent with Crohn disease, should the initial induction therapy be exclusive enteral nutrition, systemic corticosteroids, or methotrexate?
Which specialist manages Raynaud's disease?
Is carcinoembryonic antigen (CEA) useful for detecting or confirming malignant kidney cancer?
In a 7‑year‑old child with chronic diarrhea and colonoscopic skip lesions involving the terminal ileum (pediatric Crohn disease), which is the preferred initial treatment to induce remission: exclusive enteral nutrition, systemic corticosteroids, or methotrexate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question